Abstract
Management of patients with pituitary adenomas undergoing transsphenoidal surgery requires an understanding of the various medical issues relevant to the preoperative, perioperative, and postoperative states. The identification and appropriate management of tumor-induced hypopituitarism can lessen the potential for operative complications; hypopituitarism itself can be a complication of surgery requiring long-term medical management to ensure optimal health for the patient. While transsphenoidal surgery functions as the preferred management strategy for many pituitary adenomas, medical therapy is effective for several types of clinically functioning adenomas. The high efficacy of medical therapy in treating prolactinomas is well established; surgery serves an adjunctive role in this condition. Medical therapy of acromegaly and Cushing’s disease is often utilized in the setting of persistent disease after surgery or while awaiting the therapeutic effect of radiation therapy to occur. While numerous medical options are available for treating both acromegaly and Cushing’s disease, the selection of a particular agent can be a challenging endeavor requiring a thorough knowledge of the risks and benefits of each medication. An understanding of the issues relevant to medical therapy of individuals undergoing transsphenoidal surgery is critical to providing optimal multidisciplinary care to this subset of patients.
References
Friedel ME, Johnston DR, Singhal S, et al. Airway management and perioperative concerns in acromegaly patients undergoing endoscopic transsphenoidal surgery for pituitary tumors. Otolaryngol Head Neck Surg. 2013;149(6):840–4. doi:10.1177/0194599813507236.
Kamenicky P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab. 2011;96(9):2796–804. doi:10.1210/jc.2011-0536.
Pappachan JM, Raskauskiene D, Raman Kutty V, et al. Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab. 2015;100(4):1405–11. jc20143787 doi:10.1210/jc.2014-3787.
Hofland LJ, Feelders RA, de Herder WW, et al. Pituitary tumours: the sst/D2 receptors as molecular targets. Mol Cell Endocrinol. 2010;326(1-2):89–98. doi:10.1016/j.mce.2010.04.020.
Koga M, Nakao H, Arao M, et al. Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol. 1987;114(4):595–602.
Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8(1):43–52. doi:10.1007/s11102-005-5085-2.
Feldkamp J, Santen R, Harms E, et al. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study. Clin Endocrinol. 1999;51(1):109–13. cen748 [pii]
Luton JP, Thieblot P, Valcke JC, et al. Reversible gonadotropin deficiency in male Cushing’s disease. J Clin Endocrinol Metab. 1977;45(3):488–95. doi:10.1210/jcem-45-3-488.
Klibanski A. Clinical practice. Prolactinomas. N Engl J Med. 2010;362(13):1219–26. doi:10.1056/NEJMcp0912025.
Vance ML. Hypopituitarism. N Engl J Med. 1994;330(23):1651–62. doi:10.1056/NEJM199406093302306.
Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid. 1999;9(12):1167–74.
Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(4):1059–67. doi:10.1210/jc.2009-0032.
Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587–609. doi:10.1210/jc.2011-0179.
Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab. 1998;83(7):2350–4. doi:10.1210/jcem.83.7.4980.
Cunningham SK, Moore A, McKenna TJ. Normal cortisol response to corticotropin in patients with secondary adrenal failure. Arch Intern Med. 1983;143(12):2276–9.
Kristof RA, Rother M, Neuloh G, et al. Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study. J Neurosurg. 2009;111(3):555–62. doi:10.3171/2008.9.JNS08191.
Miller M, Dalakos T, Moses AM, et al. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med. 1970;73(5):721–9.
van Aken MO, Lamberts SW. Diagnosis and treatment of hypopituitarism: an update. Pituitary. 2005;8(3-4):183–91. doi:10.1007/s11102-006-6039-z.
Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, et al. Hypopituitarism. Lancet. 2007;369(9571):1461–70. S0140-6736(07)60673-4 [pii]
Lewis L, Robinson RF, Yee J, et al. Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment. Ann Intern Med. 1953;39(1):116–26.
Mah PM, Jenkins RC, Rostami-Hodjegan A, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol. 2004;61(3):367–75. doi:10.1111/j.1365-2265.2004.02106.x.
Bleicken B, Hahner S, Loeffler M, et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol. 2010;72(3):297–304. doi:10.1111/j.1365-2265.2009.03596.x.
Arlt W, Rosenthal C, Hahner S, et al. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol. 2006;64(4):384–9. CEN2473 [pii]
Plumpton FS, Besser GM, Cole PV. Corticosteroid treatment and surgery. 2. The management of steroid cover. Anaesthesia. 1969;24(1):12–8.
Martin MM. Coexisting anterior pituitary and neurohypophyseal insufficiency. A syndrome with diagnostic implication. Arch Intern Med. 1969;123(4):409–16.
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670–751. doi:10.1089/thy.2014.0028.
Fonseca V, Brown R, Hochhauser D, et al. Acute adrenal crisis precipitated by thyroxine. Br Med J (Clin Res Ed). 1986;292(6529):1185–6.
Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci. 1992;304(1):4–8.
Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22. doi:10.1056/NEJMoa1000485.
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59. doi:10.1210/jc.2009-2354.
Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72. doi:10.1210/jcem.84.10.6079.
Crofton PM, Evans N, Bath LE, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol. 2010;73(6):707–14. doi:10.1111/j.1365-2265.2010.03868.x.
Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–5. 115/7/840 [pii]
Finkel DM, Phillips JL, Snyder PJ. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. N Engl J Med. 1985;313(11):651–5. doi:10.1056/NEJM198509123131102.
Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167–77. doi:10.1210/jc.2009-0178.
Darendeliler F, Karagiannis G, Wilton P, et al. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer international growth database). Acta Paediatr. 2006;95(10):1284–90. doi:10.1080/08035250600577889.
Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999;84(11):3956–60. doi:10.1210/jcem.84.11.6113.
Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 1986;62(6):1173–9. doi:10.1210/jcem-62-6-1173.
Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol. 2006;65(4):524–9. CEN2627 [pii]
Katznelson L, Laws Jr ER, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51. doi:10.1210/jc.2014-2700.
Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40. doi:10.1210/jc.2008-0125.
Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–35. doi:10.1210/jc.2010-2443.
Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223–30. doi:10.1210/jc.2008-1533.
Godbout A, Manavela M, Danilowicz K, et al. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol. 2010;163(5):709–16. doi:10.1530/EJE-10-0382.
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88. doi:10.1210/jc.2010-1692.
Thorner MO, Martin WH, Rogol AD, et al. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab. 1980;51(3):438–45. doi:10.1210/jcem-51-3-438.
Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518–22.
Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93(12):4721–7. doi:10.1210/jc.2007-2758.
Valassi E, Klibanski A, Biller BM. Clinical review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010;95(3):1025–33. doi:10.1210/jc.2009-2095.
Molitch ME. Management of medically refractory prolactinoma. J Neuro-Oncol. 2014;117(3):421–8. doi:10.1007/s11060-013-1270-8.
Whitelaw BC, Dworakowska D, Thomas NW, et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol. 2012;76(6):877–86. doi:10.1111/j.1365-2265.2012.04373.x.
Petersenn S, Beckers A, Ferone D, et al. Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol. 2015;172(6):R227–39. doi:10.1530/EJE-14-0883.
Starke RM, Williams BJ, Vance ML, et al. Radiation therapy and stereotactic radiosurgery for the treatment of Cushing’s disease: an evidence-based review. Curr Opin Endocrinol Diabetes Obes. 2010;17(4):356–64. doi:10.1097/MED.0b013e32833ab069.
Feelders RA, Hofland LJ. Medical treatment of Cushing’s disease. J Clin Endocrinol Metab. 2013;98(2):425–38. doi:10.1210/jc.2012-3126.
Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab. 2014;99(5):1623–30. doi:10.1210/jc.2013-3628.
Greenblatt HK, Greenblatt DJ. Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol. 2014;54(12):1321–9. doi:10.1002/jcph.400.
Coppage Jr WS, Island D, Smith M, et al. Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11 beta-hydroxylation. J Clin Invest. 1959;38:2101–10. doi:10.1172/JCI103988.
Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of metyrapone in treating Cushing’s syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab. 2015;100(11):4146–54. jc20152616 doi:10.1210/jc.2015-2616.
Close CF, Mann MC, Watts JF, et al. ACTH-independent Cushing’s syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone. Clin Endocrinol. 1993;39(3):375–9.
Blanco C, Maqueda E, Rubio JA, et al. Cushing’s syndrome during pregnancy secondary to adrenal adenoma: metyrapone treatment and laparoscopic adrenalectomy. J Endocrinol Investig. 2006;29(2):164–7. 1181 [pii]
Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol. 2012;167(4):473–81. doi:10.1530/EJE-12-0358.
van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol. 1991;124(5):526–33.
Preda VA, Sen J, Karavitaki N, et al. Etomidate in the management of hypercortisolaemia in Cushing’s syndrome: a review. Eur J Endocrinol. 2012;167(2):137–43. doi:10.1530/EJE-12-0274.
Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab. 1990;70(5):1426–30. doi:10.1210/jcem-70-5-1426.
Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89(5):2452–62. doi:10.1210/jc.2003-030837.
Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914–24. doi:10.1056/NEJMoa1105743.
Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a phase III study. Clin Endocrinol. 2014;81(3):408–17. doi:10.1111/cen.12431.
Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–53. doi:10.1210/jc.2013-1771.
Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31. doi:10.1210/jc.2015-1818.
Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039–49. doi:10.1210/jc.2011-3350.
Fleseriu M, Findling JW, Koch CA, et al. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing’s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab. 2014;99(10):3718–27. doi:10.1210/jc.2014-1843.
Fleseriu M. Recent advances in the medical treatment of Cushing’s disease. F1000Prime Rep. 2014;6:18. doi:10.12703/P6-18.eCollection 2014
Barbot M, Albiger N, Ceccato F, et al. Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary. 2014;17(2):109–17. doi:10.1007/s11102-013-0475-3.
Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med. 2010;362(19):1846–8. doi:10.1056/NEJMc1000094.
Fleseriu M. The role of combination medical therapy in acromegaly: hope for the nonresponsive patient. Curr Opin Endocrinol Diabetes Obes. 2013;20(4):321–9. doi:10.1097/MED.0b013e32836318a1.
Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374–8.
Maione L, Garcia C, Bouchachi A, et al. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J Clin Endocrinol Metab. 2012;97(9):E1714–9. doi:10.1210/jc.2012-1833.
van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–9.
van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97(5):1589–97. doi:10.1210/jc.2011-2508.
Marazuela M, Paniagua AE, Gahete MD, et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab. 2011;96(2):E251–9. doi:10.1210/jc.2010-1742.
Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–73. jc.2005-0260 [pii]
Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol. 2009;70(5):757–68. doi:10.1111/j.1365-2265.2008.03441.x.
Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol. 2007;66(6):859–68. CEN2825 [pii]
Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–9. doi:10.1210/jc.2013-2480.
Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957–68. doi:10.1210/jc.2008-0027.
Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7(5):e36411. doi:10.1371/journal.pone.0036411.
Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–16. 146707 [pii]
Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91(4):1397–403. jc.2005-2347 [pii]
Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015;100(4):1699–708. doi:10.1210/jc.2014-4113.
Madsen M, Poulsen PL, Orskov H, et al. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab. 2011;96(8):2405–13. doi:10.1210/jc.2011-0654.
Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol. 2009;71(4):549–57. doi:10.1111/j.1365-2265.2009.03620.x.
Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853–9. doi:10.1210/jc.2008-0669.
Neggers SJ, de Herder WW, Feelders RA, et al. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary. 2011;14(3):253–8. doi:10.1007/s11102-010-0289-5.
Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005;365(9471):1644–6. doi:10.1016/S0140-6736(05)63011-5.
Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab. 2012;97(4):1187–93. doi:10.1210/jc.2011-2603.
Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148(4):433–42.
Beck-Peccoz P, Lania A, Beckers A, et al. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2(2):76–82. doi:10.1159/000351007.
Brucker-Davis F, Oldfield EH, Skarulis MC, et al. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999;84(2):476–86. doi:10.1210/jcem.84.2.5505.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Hong, G.K. (2017). Medical Management for Pituitary Adenoma Patients. In: Laws, Jr, E.R., Cohen-Gadol, A.A., Schwartz, T.H., Sheehan, J.P. (eds) Transsphenoidal Surgery. Springer, Cham. https://doi.org/10.1007/978-3-319-56691-7_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-56691-7_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56689-4
Online ISBN: 978-3-319-56691-7
eBook Packages: MedicineMedicine (R0)